Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 29, 2007. The report details a share repurchase transaction executed in accordance with authority granted by shareholders at the Annual General Meeting held on May 23, 2007.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 551,480 Ordinary shares of 25 pence each.
- Purchase Price: 1,311.25 pence per share.
- Treasury Shares Held: 303,069,158 shares (representing 5.03% of total voting rights).
- Shares in Issue: 5,717,445,040 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 551,480 shares on May 29, 2007. These shares are held in Treasury, increasing the total Treasury holding to 303,069,158 shares.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total number of shares in issue (5,717,445,040) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (303,069,158) and its impact on total voting rights (5.03%).
- Note that this filing is a regulatory disclosure of a specific transaction and does not contain operational performance data.